A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.
|Videos|August 28, 2020
A 66-Year-Old Woman With Mantle Cell Lymphoma
Author(s)Javier Munoz, MD, MS, FACP
Javier Munoz, MD, MS, FACP, of the Mayo Clinic, considers the appropriateness for CAR T-cell therapy for a 66-year-old woman with relapsed/refractory mantle cell lymphoma.
Advertisement
Case: A 66-Year-Old Woman With Mantle Cell Lymphoma
History
- A 66-year-old woman diagnosed with mantle cell lymphoma in 2017
- She was treated with rituximab, dexamethasone, cytarabine + carboplatin followed by autologous stem cell rescue; achieved PR;
- Continued on rituximab maintenance therapy
- In 2019 she experienced clinical relapse and was started on acalabrutinib; achieved SD
Currently
- She complains of a 3-month history of intermittent fatigue, nausea and dyspnea on exertion
- PMH: DM, medically controlled
- PE: bilateral submandibular lymphadenopathy; otherwise unremarkable
- Labs: WBC 12 X 109/L, hemoglobin 9.8 gm/dL, plt 90,000/u, LDH 410 U/I, ANC 3100/mm3
- Lymph node biopsy: IHC; cyclin D1+, CD10+, CD20+, CD43+; FISH: t (11;14)
- C/A/P CT scan: widespread lymphadenopathy including bilateral submandibular (2.9 cm, 3.4 cm), 2 left-sided axillary lymph nodes (3.7 cm, 4.1 cm), and lumbar region (5.1 cm)
- PET/CT shows diffuse uptake of 18F-FDG in the submandibular, axillary and lumbar lymph nodes
- Beta-2-microglobulin 4.2 µg/L
- Ann Arbor stage IV; MIPI score 6.6, high risk; ECOG PS 0
- Treatment was started with fludarabine + cyclophosphamide, followed by a single infusion of CAR transduced autologous T cell
Advertisement
Related to this article
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
2
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Expanding the Evidence on Lung Cancer Prevention
5